Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rubicon Launches PicoPLEX™ DNA-seq for Illumina NGS Platforms

Published: Tuesday, February 11, 2014
Last Updated: Tuesday, February 11, 2014
Bookmark and Share
PicoPLEX™ single-cell library preparation kits for IVF and other applications now available for sequencing on Illumina platforms.

Rubicon Genomics, Inc. has announced the launch of its PicoPLEX™ DNA-seq Kits for use with Illumina next-generation sequencing (NGS) platforms. PicoPLEX’s outstanding robustness and reproducibility have made it the worldwide standard for single-cell DNA amplification for microarray and PCR-based pre-implantation genetic screening and diagnosis.

PicoPLEX DNA-seq now enables researchers and clinicians to access PicoPLEX technology for analyses conducted on Illumina NGS systems.

PicoPLEX DNA-seq employs the same technology currently used by IVF clinics to detect chromosomal aneuploidies, copy number variations and single-gene disorders in reproductive cells. It is also used for the genetic characterization of other single-cell samples such as circulating tumor cells.

The easy-to-use, three-step process is performed in a single tube or well in less than three hours, thereby reducing error and contamination, speeding time to results and reducing costs.

James Koziarz, PhD, CEO of Rubicon Genomics, commented, “PicoPLEX DNA-seq emphasizes our commitment to increasing the robustness and reproducibility of DNA analyses while also delivering greater speed, efficiency and cost savings. This launch represents another milestone in our ongoing strategy to make Rubicon Genomics’ proprietary library preparation technology available to users of all sequencing platforms.”

PicoPLEX DNA-seq Kits amplify DNA to yield a highly reproducible NGS-ready library from a single cell with input concentrations of six picograms or less.

Dr. Brian Mariani, Chief Scientist and Scientific Director of the Genetics and IVF Institute, helped test the PicoPLEX DNA-seq Kits. He commented, “Remarkably, the sequencing data from the PicoPLEX DNA-seq libraries of embryo DNA clearly identified a male balanced translocation that had not been detected by previous microarray and FISH analyses. This is a significant example of how PicoPLEX sequencing data can expose important structural rearrangements missed by other approaches.”

At the 15th Annual Advances in Genome Biology and Technology (AGBT) meeting, Rubicon CSO Dr. John Langmore will discuss "Pre-implantation genetic screening and diagnostics (PGS/PGD) at low NGS coverage for aneuploidy, CNV, and single-gene disorder detection for in vitro fertilization.” AGBT 2014 will be held on Marco Island, Florida, February 12-15, 2014.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rubicon Team Up with Curio Genomics
The partnership is set up to provide ultra-fast bioinformatics software designed for use with the new Rubicon ThruPLEX® Tag-seq kits.
Thursday, September 22, 2016
SomaGenics Licenses Rights to Rubicon Genomics
SomaGenics Inc. has licensed rights of its RealSeq-AC Technology to Rubicon Genomics.
Friday, July 29, 2016
Rubicon Genomics Raises $2M
Rubicon Genomics today announced it has secured $2 million in growth capital financing.
Thursday, July 16, 2015
Rubicon Genomics Adds Global Distributors
Sales of Rubicon Genomics’ DNA library prep kit products increase over 50% as expansion of distribution channels continues.
Friday, October 17, 2014
Rubicon Genomics Adds European Distributors Ahead of New Product Launches
Company has signed agreements with seven distributors to expand the availability of its DNA library preparation products.
Saturday, June 14, 2014
Rubicon Partners with Diagenode for ChIP Sample Preparation
Combining Rubicon ThruPLEX™ and Diagenode technologies enables scientists to efficiently conduct high quality ChIP studies from small samples for NGS and array analysis.
Monday, November 05, 2012
New Data Show Rubicon’s Amplification Technology Enables Genetic and Epigenetic Analyses of Single Cells Using Next-Gen Sequencing
Data show Rubicon’s whole genome and whole Methylome Amplification kits offer key advantages for cancer, stem cell, and embryo studies.
Tuesday, November 02, 2010
Rubicon Genomics’ PicoPlex™ Technology Enables International Clinical Genetic Study of Single Human Cells
PicoPlex technology validated for accurate testing of single human cells to diagnose genetic abnormalities in advance of assisted reproduction.
Thursday, July 01, 2010
bicon Genomics, Inc. Creates Scientific Advisory Board

Friday, May 31, 2002
Rubicon Genomics, Inc. Creates Scientific Advisory Board

Friday, May 31, 2002
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!